A deep dive into Natural Capsule (NATCAPSUQ) — examining the financials, valuation picture, and who owns the stock.
Natural Capsule Revenue Trend
The top line tells a positive story: Natural Capsule's revenue advanced 9.3% to ₹170 Cr in FY2025.
Over the past 10 years, revenue has grown at a 9.7% CAGR, from ₹67.3 Cr to ₹170 Cr. Decent growth, though not exceptional.
Natural Capsule is a smaller pharmaceuticals company by revenue, with a top line of ₹170 Cr.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹170 Cr | +9.3% |
| FY2024 | ₹155 Cr | -9.8% |
| FY2023 | ₹172 Cr | +27.6% |
| FY2022 | ₹135 Cr | +69.9% |
| FY2021 | ₹79.5 Cr | — |
View Natural Capsule's full 10-year revenue trend with CAGR analysis →
Natural Capsule Profitability
Earnings pressure was evident — Natural Capsule's net profit fell 88.9% to ₹61.7 Lakh in FY2025.
The net margin narrowed from 3.6% to 0.4%, suggesting rising cost pressures.
The diluted EPS figure moved down to ₹0.22 in FY2025, against ₹6.25 posted in FY2024.
Is Natural Capsule Undervalued
The P/E Ratio model estimates an intrinsic value of ₹6, implying a 96.0% downside from the current price.
Natural Capsule shares are currently trading at ₹155.35.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹6 | 96.0% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Natural Capsule with detailed assumptions →
Natural Capsule Shareholding Pattern
No change in promoter stake — it has held at 51.0% for the past 4 quarters.
No movement from FIIs — their 0.0% holding is unchanged year-over-year.
DII holding has been steady at 0.0% — no change from the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 51.0% | 0.0% | 0.0% | 49.0% |
| Dec 2025 | 51.3% | 0.0% | 0.0% | 48.7% |
| Sep 2025 | 51.3% | 0.0% | 0.0% | 48.7% |
| Jun 2025 | 51.3% | 0.0% | 0.0% | 48.7% |
Track quarterly shareholding changes for Natural Capsule →
Natural Capsule Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹4.19B, up 11.4% YoY from ₹3.77B.
Property, Plant & Equipment accounts for 67.3% of the total, ahead of Receivables (14.8%) and Other Assets (10.9%).
Capital structure: 61.3% equity, 25.1% debt, 13.6% operating liabilities. Over the year, debt is down 3.5% and equity is up 12.4%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 6.89M |
| Receivables | 622.41M |
| Inventories | 254.57M |
| Property, Plant & Equipment | 2.82B |
| Investments | 27.30M |
| Other Assets | 459.02M |
| Category | Value |
|---|---|
| Equity | 2.57B |
| Short-term Debt | 477.69M |
| Long-term Debt | 574.25M |
| Trade Payables | 385.07M |
| Other Liabilities | 184.89M |
Natural Capsule Key Highlights
To sum up Natural Capsule's financial position: the data paints a clear picture for investors evaluating this pharmaceuticals stock.
Revenue of ₹170 Cr in FY2025, up 9.3% year-over-year.
Long-term revenue has been compounding at 9.7% annually over 10 years.
The company is profitable, with a net margin of 0.4% and net income of ₹61.7 Lakh.
The P/E Ratio model implies 96.0% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Natural Capsule.